High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis

High-dose vs low-dose steroid in pregnancy patients... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/11-543" }, "headline": "High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A...", "datePublished": "2022-05-19T11:19:12", "dateModified": "2022-05-19T11:19:12", "author": [ { "@type": "Person", "name": "Mochammad Thaha" }, { "@type": "Person", "name": "Mochamad Yusuf Alsagaff" }, { "@type": "Person", "name": "Satriyo Dwi Suryantoro" }, { "@type": "Person", "name": "Mutiara Rizky Hayati" }, { "@type": "Person", "name": "Hendri Susilo" }, { "@type": "Person", "name": "Alfian Nur Rosyid" }, { "@type": "Person", "name": "Tri Pudy Asmarawati" }, { "@type": "Person", "name": "Emil Prabowo" }, { "@type": "Person", "name": "Ibrahim Syamsuri" }, { "@type": "Person", "name": "Rais Hakim" }, { "@type": "Person", "name": "Muhammad Ilham Aldika Akbar" }, { "@type": "Person", "name": "Cahyo Wibisono Nugroho" }, { "@type": "Person", "name": "Yusuke Suzuki" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "Background: Management of systemic lupus erythematosus (SLE) and lupus nephritis (LN) in pregnancy has been improving in recent decades. However, SLE can still lead to adverse pregnancy outcomes if not appropriately treated. Optimal dose of steroids, as one of the most commonly used for the treatment of SLE and LN in pregnancy is still a subject of debate. In this review, we determine the pregnancy outcomes in SLE and LN patients treated with low vs high doses of steroids. Methods: ProQuest, Pubmed, Science Direct, Scopus, and Web of Science were carefully searched for relevant studies published in English. A total of 2,596 studies were reviewed. We extracted the data from previous studies showing the use of steroids treatment in high-dose and low-dose related to pregnancy outcomes. We provide larger data about maternal (preterm rupture of membrane, fetal loss, pre-eclampsia, and flare up) and fetal outcomes (prematurity, small gestational age, low birth weight) receiving high vs low steroid in patients with SLE and LN in this systematic review and meta-analysis. Results: A total of 13 studies were included. Of these, one study discussed a group with LN and 12 other studies discussed SLE with related maternal and fetal outcomes. Maternal outcome in the group with low-dose steroid showed a lower risk of fetal loss (odds ratio (OR): 1.93; 95% confidence interval (CI) 1.01-3.70), but there were no differences in other maternal outcomes. The low-dose steroid group showed a better fetal outcome, with a lower risk of prematurity (OR: 3.06; 95% CI 1.98-4.71), small gestational age (OR: 2.63; 95% CI 1.15-6.00), and low birth weight (OR: 2.43; 95% CI 1.23-4.79). Conclusions: In pregnant patients with SLE or LN, high-dose steroids are associated with the high risk of fetal loss during pregnancy, preterm birth, small gestational age, and low birth weight." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/11-543", "name": "High-dose vs low-dose steroid in pregnancy patients with systemic..." } } ] } Home Browse High-dose vs low-dose steroid in pregnancy patients with systemic... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Thaha M, Alsagaff MY, Dwi Suryantoro S et al. High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis [version 1; peer review: 1 approved] . F1000Research 2022, 11 :543 ( https://doi.org/10.12688/f1000research.109908.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Systematic Review High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis [version 1; peer review: 1 approved] Mochammad Thaha https://orcid.org/0000-0001-5180-957X 1,2 , Mochamad Yusuf Alsagaff https://orcid.org/0000-0003-2194-6850 2,3 , Satriyo Dwi Suryantoro https://orcid.org/0000-0002-0522-8659 1,2 , [...] Mutiara Rizky Hayati https://orcid.org/0000-0002-0903-822X 2 , Hendri Susilo https://orcid.org/0000-0002-5603-9487 2,3 , Alfian Nur Rosyid 2,4 , Tri Pudy Asmarawati https://orcid.org/0000-0001-9869-5098 1,2 , Emil Prabowo https://orcid.org/0000-0002-3552-4766 5 , Ibrahim Syamsuri https://orcid.org/0000-0003-0095-240X 5 , Rais Hakim 5 , Muhammad Ilham Aldika Akbar 2,6 , Cahyo Wibisono Nugroho 1,2 , Yusuke Suzuki 7 Mochammad Thaha https://orcid.org/0000-0001-5180-957X 1,2 , Mochamad Yusuf Alsagaff https://orcid.org/0000-0003-2194-6850 2,3 , [...] Satriyo Dwi Suryantoro https://orcid.org/0000-0002-0522-8659 1,2 , Mutiara Rizky Hayati https://orcid.org/0000-0002-0903-822X 2 , Hendri Susilo https://orcid.org/0000-0002-5603-9487 2,3 , Alfian Nur Rosyid 2,4 , Tri Pudy Asmarawati https://orcid.org/0000-0001-9869-5098 1,2 , Emil Prabowo https://orcid.org/0000-0002-3552-4766 5 , Ibrahim Syamsuri https://orcid.org/0000-0003-0095-240X 5 , Rais Hakim 5 , Muhammad Ilham Aldika Akbar 2,6 , Cahyo Wibisono Nugroho 1,2 , Yusuke Suzuki 7 PUBLISHED 19 May 2022 Author details Author details 1 Department of Internal Medicine, Faculty of Medicine Universitas Airlangga, Surabaya, 60132, Indonesia 2 Universitas Airlangga Hospital, Surabaya, 60115, Indonesia 3 Department of Cardiology and Vascular Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia 4 Department of Pulmonology and Respiratory Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia 5 Universitas Airlangga, Surabaya, 60132, Indonesia 6 Department of Obstetrics and Gynecology, Universitas Airlangga, Surabaya, 60132, Indonesia 7 Department of Nephrology, Jutendo University, Tokyo, 113-8421, Japan Mochammad Thaha Roles: Conceptualization, Data Curation, Project Administration, Supervision Mochamad Yusuf Alsagaff Roles: Investigation, Methodology, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing Satriyo Dwi Suryantoro Roles: Investigation, Project Administration, Supervision Mutiara Rizky Hayati Roles: Investigation, Methodology Hendri Susilo Roles: Investigation, Supervision, Writing – Review & Editing Alfian Nur Rosyid Roles: Investigation, Supervision, Writing – Review & Editing Tri Pudy Asmarawati Roles: Data Curation, Formal Analysis, Investigation, Methodology, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing Emil Prabowo Roles: Investigation, Software, Visualization, Writing – Original Draft Preparation Ibrahim Syamsuri Roles: Investigation, Software, Visualization, Writing – Original Draft Preparation Rais Hakim Roles: Investigation, Writing – Original Draft Preparation Muhammad Ilham Aldika Akbar Roles: Validation, Writing – Review & Editing Cahyo Wibisono Nugroho Roles: Supervision, Validation, Writing – Review & Editing Yusuke Suzuki Roles: Validation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background: Management of systemic lupus erythematosus (SLE) and lupus nephritis (LN) in pregnancy has been improving in recent decades. However, SLE can still lead to adverse pregnancy outcomes if not appropriately treated. Optimal dose of steroids, as one of the most commonly used for the treatment of SLE and LN in pregnancy is still a subject of debate. In this review, we determine the pregnancy outcomes in SLE and LN patients treated with low vs high doses of steroids. Methods: ProQuest, Pubmed, Science Direct, Scopus, and Web of Science were carefully searched for relevant studies published in English. A total of 2,596 studies were reviewed. We extracted the data from previous studies showing the use of steroids treatment in high-dose and low-dose related to pregnancy outcomes. We provide larger data about maternal (preterm rupture of membrane, fetal loss, pre-eclampsia, and flare up) and fetal outcomes (prematurity, small gestational age, low birth weight) receiving high vs low steroid in patients with SLE and LN in this systematic review and meta-analysis. Results: A total of 13 studies were included. Of these, one study discussed a group with LN and 12 other studies discussed SLE with related maternal and fetal outcomes. Maternal outcome in the group with low-dose steroid showed a lower risk of fetal loss (odds ratio (OR): 1.93; 95% confidence interval (CI) 1.01-3.70), but there were no differences in other maternal outcomes. The low-dose steroid group showed a better fetal outcome, with a lower risk of prematurity (OR: 3.06; 95% CI 1.98-4.71), small gestational age (OR: 2.63; 95% CI 1.15-6.00), and low birth weight (OR: 2.43; 95% CI 1.23-4.79). Conclusions: In pregnant patients with SLE or LN, high-dose steroids are associated with the high risk of fetal loss during pregnancy, preterm birth, small gestational age, and low birth weight. READ ALL READ LESS Keywords systemic lupus erythematosus, lupus nephritis, steroid, high dose, low dose, health Corresponding Author(s) Mochammad Thaha ( [email protected] ) Close Corresponding author: Mochammad Thaha Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2022 Thaha M et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Thaha M, Alsagaff MY, Dwi Suryantoro S et al. High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis [version 1; peer review: 1 approved] . F1000Research 2022, 11 :543 ( https://doi.org/10.12688/f1000research.109908.1 ) First published: 19 May 2022, 11 :543 ( https://doi.org/10.12688/f1000research.109908.1 ) Latest published: 19 May 2022, 11 :543 ( https://doi.org/10.12688/f1000research.109908.1 ) Introduction Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that can manifest as mucocutaneous, hematologic, neurologic, and renal. 1 This condition affects mostly women of childbearing age. In 1996, the prevalence of women diagnosed with SLE in the United Kingdom in 18 to 65 year olds was 54 per 100,000 cases, 2 , 3 while prevalence in 2012 increased significantly into 97.04 per 100,000 cases with the mean age of 49 years old. 4 It makes SLE one of the most common autoimmune diseases in pregnancy. Pregnancy and SLE worsen each other. Adverse effects of SLE in pregnancy include pre-eclampsia or eclampsia, preterm birth, preterm premature rupture of the membrane, intrauterine growth restriction (IUGR), and fetal loss. 5 Hypertensive complications, such as pre-eclampsia (PE)/eclampsia (eclampsia), pregnancy-induced hypertension (PIH), and hemolysis, and elevated liver enzymes and low platelets (HELLP) syndrome, are major concern for SLE pregnant patients, especially those with anti-phospolipid autoantibodies (aPL) positivity/antiphospholipid syndrome (APS) and lupus nephritis (LN). 6 On the other hand pregnancy may increase SLE activity or induce flare that may lead to unfavorable symptoms. 7 In the past decade, physicians contraindicated pregnancy in SLE. 8 Nevertheless, with the improvement of therapy and management, pregnant women with SLE could have better outcomes and prognosis. 9 A recent comprehensive review of several countries within the past 40 years showed that the rate of fetal loss has decreased from 40% to 17%, whereas the most recent studies found a pregnancy loss rate of 10% to 25%. 6 Steroids are the most common therapy for autoimmune and inflammatory disease including SLE to manage flare or maintain therapy. 10 – 12 It has a dual contradicting effect in the treatment of SLE with pregnancy, either making it better and worse. Data showed that increasing dose are also followed by increasing risk of adverse effects. 13 During pregnancy, steroid exposure can affect placental growth and gene expression resulting in poor nutrition and gas exchange for the fetus, 14 , 15 hence it should be limited to a minimum level. High doses during pregnancy have been linked to a higher risk of diabetes, hypertension, pre-eclampsia, and premature membrane rupture. 16 Short courses of high dosages and/or intravenous pulse methylprednisolone can be administered in the case of disease flares. 17 With the lack of information about steroids dose for therapy of SLE in pregnancy, we examine the outcome of pregnancy after low or high dose steroids in this systematic review and meta-analysis. Objectives The objective of this systematic review and meta-analysis was to examine the effect on high-dose vs low dose of steroid in maternal and fetal outcomes in patients with SLE and LN. Methods Databases and search We conducted an electronic literature search from online databases, ProQuest , Pubmed , Scopus , Science Direct , and Web of Science . In addition, reference lists from previous reviews that had articles related to our criteria for inclusion were searched and literature was included where appropriate. The search was conducted in October 2021 and the last search on each database was on 26 November 2021. Literature searching was done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 18 We used a protocol included in the Cochrane Collaboration’s search strategy for randomized control trials with the following terms used to search each database: (systemic lupus erythematosus) OR (SLE) OR (lupus nephritis) OR (LN) AND (pregnancy outcome*) OR (pregnancy complication*) OR (maternal outcome*) OR (maternal complication*) OR (fetal outcome*) OR (fetal complication*) OR (adverse pregnancy outcome*) OR (obstetrical outcome*). No filters and limit used in our search strategy. The search terms used for each database can be found as Extended data . 47 Selection criteria We included studies based on the following criteria: (1) The studies were randomized control trials, cohort, case-control, or cross-sectional; (2) Studies reported maternal and fetal complications in pregnant women with SLE or LN; (3) Studies reported high-dose steroid and low-dose steroid groups; (4) English language publication. Studies were excluded when meeting the following criteria: (1) They were case report, case series, literature review, systematic review, and meta-analysis; (2) Studies did not report the outcome of pregnancy-related to the group of steroids; (3) Duplicated studies. The searches were performed by author RH. Two authors (EP and IS) independently screened all titles and abstracts, and retrieved the full text of any articles that met the aforementioned criteria. Both authors reviewed full text articles’ eligibility, and disagreement between two authors was resolved by discussion. This process of selection, including the removal of duplicate studies, and reviewing abstracts and full texts was carried out using platform COVIDENCE , a web-based platform designed for the process of systematic reviews. Outcome measures The following maternal outcomes were reported: pre-eclampsia/eclampsia, premature rupture of membranes (PROM), flares, oligohydramnios, pregnancy-induced hypertension (PIH), and fetal loss. The fetal outcomes studied were: live birth, preterm birth (under 37 weeks gestational age), small gestational age (SGA), and low birth weight (LBW). We defined the outcomes as follows: Maternal outcomes definition : (1) Preeclampsia: Preeclampsia is gestational hypertension with one of the following new-onset disorders at or after 20 weeks of pregnancy such as proteinuria, other organ dysfunction including kidney, liver, neurological and hematological involvement, and uteroplacental dysfunction; 19 (2) Eclampsia: Seizure that occurs in pregnant women with preeclampsia; 20 (3) Preterm Rupture Of the Membranes (PROM): Ruptures of the amniotic sac membranes in pregnant women at gestational age at or 37 weeks before the onset of labor; 21 (4) Oligohidramnion: Decreased amniotic fluid volume less than expected gestational age. it can be identified by procedures using ultrasonography with the result of amniotic fluid index lower than 5 centimeters; 22 (5) Gestational Hypertension (GH): Chronic de novo hypertension which occurs at or after 20 weeks’ pregnancy with no manifestations of preeclampsia; 19 (6) Pregnancy loss: 1) spontaneous abortion: loss of pregnancy less than 20 weeks of gestational age 2) Intrauterine Fetal Death (IUFD): loss of pregnancy more than 20 weeks of gestational age or fetal weight over than 350 gram 3) stillbirth: loss of pregnancy before or during pregnancy. We defined three of them as pregnancy loss; 23 (7) SLE flare: 1) signs of new active disease observed through clinical and laboratory factors or change in therapy; 2) elevation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score; 24 3) elevation of Lupus Activity Index in Pregnancy; 25 5) elevation of physician global assessment; 26 4) elevation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) score. 27 Fetal outcomes definition : (1) Live birth: baby born alive during labor 28 ; (2) Preterm birth: the birth of a baby at gestational age before 37 weeks 29 ; (3) Small gestational age (SGA) or Intrauterine growth retardation (IUGR): newborn baby or fetal weight less than 10th percentile for gestational age 30 ; (4) Low birth weight (LBW): newborn baby weight less than 2500 grams. 28 Data extraction Data extraction was carried out by pairs of reviewers (EP, IS), and any disagreements were determined by consensus in the team. The studies were then screened for relevance, and those meeting the eligibility criteria were included in the review. In this process, we utilized COVIDENCE , though RevMan 5.4 could be used as an open-source alternative. If the data represented in the article were unclear, we contacted the corresponding authors of each study to clarify and ask for additional data if needed. We extracted data from each study using a predesigned table. Data collected were methodological data, mean maternal age during pregnancy, group of high-dose, low-dose steroid, and the related pregnancy outcomes. We used each study’s definition of high-dose or low-dose steroid and the doses were equalized to prednisone equivalent. If the study did not mention the definition of high-dose and low-dose of steroid, we used recommendations from the 2020 American College of Rheumatology (ACR) Guideline 31 ; i.e. if a group received >10 mg/day of prednisone equivalent, it would be considered as high-dose. Quality assessment The quality of the observational studies was reviewed independently by EP and IS using the Newcastle-Ottawa Scale (NOS). 7 The bias was reviewed by the following parameters: selection, comparability, and exposure or outcome. The total score will be 9 for cohort and 8 for cross-sectional studies. Total score ≥ 7 for cohort and ≥ 6 for cross-sectional studies were used to conclude high-quality studies. 7 Disagreements were resolved by consensus. The funnel plots were used to help assess bias of missing results in each study. Statistical analysis We used RevMan (5.4) software for statistical analysis. Data were represented by Odds Ratio (OR) with 95% confidence intervals calculated for maternal and fetal outcomes. Heterogeneity among studies was assessed by the Q-test and I 2 statistic. Subgroup analysis with a p-value equal to or less than.05 was considered statistically significant. Low heterogeneity was defined by an I 2 value in the range of 25% and 50 between 50% and 75% for moderate heterogeneity, and greater than 75% as high heterogeneity. We did Egger’s test and a funnel plot for publication bias (p<0.05 was considered statistically significant). Ethics statement This study was approved by Airlangga Hospital’s ethical board, certificate number 189/KEH/2019. All analyses for the present study were based on previous published research, thus no patient consent was required. This article is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 47 Results Study selection A flow chart of the study selection process is shown in Figure 1 . We identified a total of 2,596 studies using search terms from our aforementioned databases. A total of 1,441 duplicated studies were removed. Following screening title and abstract we excluded irrelevant 797 studies, 305 full-text studies were reviewed for eligibility, and finally, a total of 13 studies were included in our quantitative synthesis for systematic review and meta-analysis. Figure 1. PRISMA flowchart for included studies. Study characteristics Of 13 studies, nine studies were cohort retrospective, while four studies were cohort prospective. The main characteristics are shown in Table 1 . The studies were conducted in various regions such as Canada, China, Italy, Ghana, London, Thailand, Japan, and USA. The patient’s enrollment was from 1996 to 2020. The majority of women included in the study were Asian (53%) ( Table 1 ). The average maternal age was 29 ± 3,09 years old. From the data, most women with SLE received a low-dose steroids (72,2%) than high-dose steroids (27,8%) treatments, with the average cut-off used to classify high-dose steroids was 11,78 mg. A total of participants in the experimental (high dose steroids) group were 448 patients (48 patients were LN) and the control (low dose steroids) group were 1,289 patients (82 patients were LN) ( Table 3 ). Table 1. Main and baseline features of the included studies. OR, odds ratio; ROC, receiver operating characteristic; RR, risk ratio; HR, hazard ratio. Study Year Design Region Years of patients' enrolment Maternal age ± (years) Patients receive high-dose steroid * (n) Patients receive low-dose steroid * (n) Cut off for high-dose steroid * (/day) Statistical outcomes Additional data Clark et al . 32 2003 Cohort Retrospective Canada 1999-2001 30.96 ± 3.9 14 5 ≥10 mg p value - Dey et al . 33 2016 Cohort Retrospective Ghana 2013-2014 30.1 4 3 >10 mg prevalence - Doria et al . 34 2002 Cohort Prospective Italy NR 30.5 7 7 >10 mg prevalence - Englert el al. 35 1988 Cohort Prospective London 1983-1985 NR 9 11 ≥15 mg prevalence - Foocharoen et al . 36 2009 Cohort Retrospective Thailand 1997-2006 27.3 ± 3.26 9 9 >15 mg prevalence - Kobayasshi et al . 37 1999 Cohort Prospective Japan 1982-1997 29.7 ± 3.8 5 61 >15 mg prevalence - Louthrenoo et al . 38 2021 Cohort Prospective Thailand 1993-2007 26.94 ± 4.80 10 61 >10 mg - OR Murata et al . 39 2021 Cohort Retrospective Japan 2006-2020 31.4 ± 4.6 5 47 >15 mg p value ROC Oishi et al . 40 2021 Cohort Retrospective Japan 1996-2018 30.0 20 49 ≥10 mg - OR, ROC analysis Palmsten et al . 13 2021 Cohort Retrospective USA 2007-2013 27.9 ± 5.8 49 174 Average 15.2 ± 6.4 - RR, HR Takahashi et al . 41 2013 Cohort Retrospective Japan 1995-2013 30.7 ± 4.6 47 26 ≥7.5 mg p value - Ueda et al . 42 2020 Cohort Retrospective Japan 2005-2019 32.5 ± 1.16 5 43 >10.5 mg p value - Zhang et al . 43 2020 Cohort Retrospective China 2012-2017 25.74 ± 4.67 28 55 ≥10 mg Mean SD OR, ROC analysis * Prednisone equivalent dose. Pregnancy outcomes This research divided the outcomes into two groups: maternal outcomes and fetal outcomes. The maternal outcomes reported were as follows: fetal loss, PROM, pre-eclampsia, oligohydramnios, PIH, and flares. Five of 13 studies discussed fetal loss as a maternal outcome. In the fetal outcomes group, the studies analyzed pre-term, LBW, and SGA. The majority of studies (8/13) discussed pre-term labor as an outcome ( Table 2 ). The SLE diagnostic criteria used for these studies have many variations. The majority of studies were using the ACR 1997 Criteria as reference ( Table 2 ). The criteria used for disease activity also varied in each study. In most studies, the disease severity was defined by organ involvement and laboratory abnormalities, whereas five studies used the systemic lupus disease activity index (SLEDAI) ( Table 2 ). There were also various criteria for defining flares in patients. Most of the studies used flares criteria based on signs of new disease activity either by clinical or laboratory and change in therapy, and 3 other studies used the SLEDAI score ( Table 2 ). Table 2. Outcomes reported, diagnosis criteria and Newcastle-Ottawa Score (NOS). Study Disease population Maternal outcomes related to steroid dose Fetal outcomes related to steroid dose SLE diagnostic criteria Disease activity Flare NOS Score Clark et al . 32 SLE - Pre-term 2 3 3 8 Dey et al . 33 SLE Fetal loss - 1 4 4 8 Doria et al . 34 SLE PROM, pre-eclampsia, oligohidramnion Pre-term 2 5 4 7 Englert el al. 35 SLE Fetal loss Pre-term, LBW 2 NR NR 7 Foocharoen et al . 36 SLE Abortion (fetal loss) - 1 4 4 8 Kobayasshi et al . 37 SLE PROM Pre-term, SGA 2 4 4 8 Louthrenoo et al . 38 SLE PROM, PIH, flares, fetal loss Pre-term, SGA, LBW 1 2 5,6,7 8 Murata et al . 39 SLE PROM, pre-eclampsia Pre-term, SGA, LBW 1 3,4 3 8 Oishi et al . 40 LN - Pre-term, LBW 1 1,4 4 8 Palmsten et al . 13 SLE - Pre-term 3 NR NR 8 Takahashi et al . 41 SLE Pre-eclampsia, flare up - 1 3,4 4,8 8 Ueda et al . 42 SLE Flare - 1 3,4 3,4 8 Zhang et al . 43 SLE Fetal loss - 1 3 5 8 Risk of bias assessment For cohort and cross-sectional studies, The Newcastle-Ottawa Score (NOS) was used to evaluate the risk of bias in this study. Table 2 shows the NOS scores from each study. For the cohort studies, the total NOS score was 9. The majority of studies (11/13) have an average score of 8, and two other studies have a score of 7. All of the studies are high quality and have low-risk of bias. We used Egger’s test to evaluate the possibility of publication bias. No indication of publication bias (p<0.05) for all outcomes were detected. Preterm rupture of membrane (PROM) Four studies (n=202) with outcomes of PROM were included in the meta-analysis. The risk of PROM in high-dose steroids were not significantly difference compared with low-dose steroids group (OR 1.14, 95% CI 0.44 to 2.98, p=0.79, I 2 =38%) ( Table 3 ). Table 3. Comparison high vs low-dose steroid for maternal and fetal outcomes. Maternal outcome Outcomes N Mode Value pE pHet P OR 95% CI High-dose steroid Low-dose steroid n Total n Total PROM 202 Fixed 6 41 25 161 0.81 0.19 0.79 1.14 0.44-2.98 Fetal Loss 217 Fixed 24 61 37 156 0.42 0.50 0.05 1.93 1.01-3.70 Pre-eclampsia 163 Fixed 9 60 17 103 0.61 0.22 0.58 1.30 0.51-3.30 Flare up 235 Random 23 68 67 167 0.89 0.03 0.50 1.77 0.33-9.41 Fetal Outcome Outcomes N Mode Value pE pHet P OR 95% CI High-dose steroid Low-dose steroid n Total n Total Prematurity 526 Fixed 78 134 139 392 0.32 0.53 <0.00001 3.06 1.98-4.71 SGA 178 Fixed 13 31 33 147 0.35 0.47 0.02 2.63 1.15-6.00 LBW 216 Fixed 33 53 71 163 0.49 0.19 0.01 2.43 1.23-4.79 Fetal loss Five studies (n=217) with the fetal loss evaluated were included in the meta-analysis. High-dose steroids were associated with a higher risk of fetal loss as compared to low-dose steroids (OR 1.93, 95% CI 1.01 to 3.70, p=0.05, I 2 =0%) ( Table 3 ). Pre-eclampsia Only three studies (n=168) were included in the meta-analysis in relation to preeclampsia outcomes. The risk of preeclampsia in high-dose steroids were not significantly difference compared with low-dose steroids group (OR 1.30, 95% CI 0.51 to 3.30, p=0.58, I 2 =35%) ( Table 3 ) . Flare Three studies (n=235) were included in the meta-analysis. The risk of disease flare in high-dose steroids were not significantly difference compared with low-dose steroids group (OR 1.77, 95% CI 0.33 to 9.41, p=0.50, I 2 =73%) ( Table 3 ). Preterm birth Eight studies (n=526) were included in the meta-analysis for preterm birth outcome. One study discussed LN. Higher risk or preterm delivery were more associated with high-dose steroids than low-dose steroids (OR 3.06, 95% CI 1.98 to 2.22, p<0.00001, I 2 =0%) ( Table 3 ). Small gestational age (SGA) Four studies (n=178) were included in the meta-analysis. High-dose steroids were associated with a higher risk of SGA as compared with low-dose steroids (OR 2.63, 95% CI 1.15 to 6.00, p=0.02, I 2 =0%) ( Table 3 ). Low birth weight (LBW) Five studies (n=216) were included in the meta-analysis. The risk of LBW in high-dose steroids were not significantly difference compared with low-dose steroids group (OR 2.43, 95% CI 1.23 to 4.79, p=0.01, I 2 =34%) ( Table 3 ). Funnel plots were also done which can be found as Extended data . 47 Comparison and detail about outcomes are provided in Figures 2 , 3 , 4 , 5 and Table 3 . 47 Maternal outcomes Fetal loss during pregnancy Figure 2. Fetal loss during pregnancy in high-dose versus low-dose steroids. Fetal outcomes Prematurity Figure 3. Prematurity in high versus low-dose steroids. Small gestational age Figure 4. Small gestational age in high versus low-dose steroids. Low birth weight Figure 5. Low birth weight in high versus low-dose steroids. Discussion In this systematic review, we examine 13 papers that evaluate at how steroid dose affects pregnancy outcomes in SLE and LN patients. Overall, we discovered that high steroid doses were linked to a higher risk for adverse maternal outcomes, particularly pregnancy loss. Furthermore, increased risks of poor fetal outcomes, such as premature birth, low birth weight, and small gestational age, were linked to high-dose steroid use during pregnancy. Low-dose steroids were given to more SLE patients in this study than high-dose steroids, which were classified as >10 mg/day of prednisone equivalent. The number of pregnancy losses was considerably higher in the high-dose steroid group than in the low-dose steroid group. Furthermore, the premature delivery rate was 58 percent among all live births. We used a comprehensive search strategy and careful appraisal following a standard protocol for systematic review to assess the validity of study results. The selected studies mostly have similar characteristics of enrolled patients with respect to age, race, criteria used for diagnosis and disease activity. All of the studies were high quality with low-risk of bias and no indications of publication bias from Egger test. Premature delivery, intrauterine development retardation, and fetal death in pregnant women with SLE were highly associated with steroid dose reflecting managed disease, as well as disease flare-ups during pregnancy, according to our findings. To the best of our knowledge, this is the first meta-analysis that discussed the relationship between steroids and fetal or maternal outcomes in SLE and LN patients. In a previous systematic review, Wu et al . reported prevalence of adverse pregnancy outcomes in SLE with LN and identified their significant association. 7 However, the study did not look at the differences in the occurrence of the aforementioned outcomes between individuals who were given a high steroid dose and those who were given a low steroid dose. Another meta-analysis showed that higher rates of maternal and fetal complications including preeclampsia, hypertension, fetal loss, premature birth, SGA and congenital defects were strongly associated with SLE. 44 Nevertheless, the included studies were limited and antenatal management using steroids was not mentioned. High blood pressure, active nephritis, and the antiphospholipid syndrome (APS) in SLE flares up seemed to be the major factors behind the adverse pregnancy outcomes. The role of steroids to control the flare and maintenance therapy in patients with remission are widely used. In both acute and chronic settings, the use of steroids during pregnancy is the preferred choice for a myriad of maternal and fetal purposes. 45 In many fetal tissues, such as the liver, lungs, stomach, skeletal muscle, and adipose tissue, steroids are vital for the growth and development to prepare for the life outside the womb. Steroids control prostaglandin production, which has been linked to key roles during implantation by improving stromal vascular permeability and employed in the treatment of mothers who are at risk of preterm delivery. 45 , 46 Their abilities to inhibit the immune system and reduce inflammation are frequently used to control the severity of a patient's condition and flares in pregnant women with autoimmune disorders, such as SLE. 46 In a cohort study on preterm deliveries in women with SLE, Clark et al . demonstrated that lower dose of steroid maintained through pregnancy was associated with extending SLE pregnancies to full term, thus lowering maternal and fetal morbidity. 32 On the other hand, Zhang et al . stated that increased fetal loss was not associated with the prednisone dose in pregnant women with SLE, whereas combined APS and SLEDAI were the key risk factors of those complication. All abovementioned results represent limited discussion about optimal doses of steroids to improve the outcome of SLE women. Along with varying population, study design, diagnostic criteria, statistical method, and outcomes reported. This systematic review combined a larger population to provide the risk of steroids in pregnancy outcomes to support the need for dose adjustment of steroid in patients with active SLE and consideration for avoidance of pregnancy until all manifestations are quiscent. This study came with some limitations. Our team did not find eligible randomized control trials that study about pregnancy outcome related to the dose of steroid due to limited studies and ethically improper to perform. Most of our included studies were retrospective-observational studies that are more prone to bias and cofounding. We only include the English studies, as consequence the non-English studies that met our criteria could not be reviewed. We did not conduct subgroup analysis of the dosage, route of administration, and kind of steroid. Each center has customary steroid administration in patients with SLE and LN; therefore, to apply the result of this study, clinicians should firstly ensure the indication and determine the most optimal and safe dosage to achieve a good maternal and fetal outcome. Some studies only had small samples with insufficient total samples to be generalized to the entire population. Further observation with larger population on the side effects of steroid in combination with another agent, e.g., immunosuppressants, is required to evaluate maternal and fetal outcome. Conclusions Steroids are used to overcome SLE and LN in pregnancy. High-dose steroids may increase the risk of preterm birth and miscarriage during pregnancy. Besides, it may also cause deterioration, seen in other variables of the maternal and fetal outcome. Data availability Underlying data Figshare: Data of High-dose vs Low-dose Steroid in Pregnancy Patients with Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-analysis, https://doi.org/10.6084/m9.figshare.18514970.v5 . 47 This project contains the following underlying data: ‐ High vs Low Dose Steroid in Pregnancy Patients with SLE.rm5 (the data of each study used to create the forest and funnel plots. The open source software RevMan is required to open this file). Extended data Figshare: Data of High-dose vs Low-dose Steroid in Pregnancy Patients with Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta analysis, https://doi.org/10.6084/m9.figshare.18514970.v5 . 47 This project contains the following extended data: ‐ PubMed 25 Nov.png (search terms in Pubmed database). ‐ Proq-96-25nov.png (search terms in ProQuest database). ‐ SciDir-25nov-138.png (search terms in Science Direct database). ‐ Scopus-nov-670.png (search terms in Scopus database). ‐ Wos-467-25nov.png (search terms in Web of Science database). ‐ PRISMA flow.png (PRISMA flow diagram) ‐ Funnel plot_PROM.svg ‐ Funnel plot_Fetal Loss.svg ‐ Funnel plot_Flare up.svg ‐ Funnel plot_LBW.svg ‐ Funnel plot_Prematurity.svg ‐ Funnel plot_Pre eclampsia.svg ‐ Funnel plot_SGA.svg Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Reporting guidelines Figshare: PRISMA checklist for ‘High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis’, https://doi.org/10.6084/m9.figshare.18514970.v5 . 47 References 1. Dalal DS, Patel KA, Patel MA: Systemic L Erythematosus and Pregnancy: A Brief Review. J. Obstet. Gynecol. India 2019; 69 : 104–109. Publisher Full Text 2. Lim SS, Drenkard C: Epidemiology of lupus: An update. Vol. 27, Current Opinion in Rheumatology. Lippincott Williams and Wilkins; 2015; 427–432. 3. Pons-Estel GJ, Alarcón GS, Scofield L, et al. : Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. Semin. Arthritis Rheum. 2010; 39 : 257–268. PubMed Abstract | Publisher Full Text 4. Rees F, Doherty M, Grainge M, et al. : The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann. Rheum. Dis. 2016 Jan; 75 (1): 136–141. 5. Petri M: Pregnancy and Systemic Lupus Erythematosus. Best Pract. Res. Clin. Obstet. Gynaecol. 2020 Apr; 64 : 24–30. Publisher Full Text 6. Lazzaroni MG, Dall’Ara F, Fredi M, et al. : A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus. J. Autoimmun. 2016 Nov; 74 : 106–117. PubMed Abstract | Publisher Full Text 7. Wu J, Ma J, Zhang WH, et al. : Management and outcomes of pregnancy with or without lupus nephritis: a systematic review and meta-analysis. Ther. Clin. Risk Manag. 2018 May 11 [cited 2022 Jan 16]; Volume 14 : 885–901. PubMed Abstract | Publisher Full Text 8. Clark CA, Spitzer KA, Laskin CA: Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J. Rheumatol. 2005 Sep; 32 (9): 1709–1712. PubMed Abstract 9. Knight CL, Nelson-Piercy C: Management of systemic lupus erythematosus during pregnancy: challenges and solutions. Open Access Rheumatol. 2017 Mar 10 [cited 2022 Jan 16]; 9 : 37–53. PubMed Abstract | Publisher Full Text 10. Ateka-Barrutia O, Khamashta MA: The challenge of pregnancy for patients with SLE. Lupus. 2013 Oct [cited 2022 Jan 16; 22 (12): 1295–1308. Reference Source 11. Ferguson CB, Mahsud-Dornan S, Patterson RN: Inflammatory bowel disease in pregnancy. BMJ. 2008 Jul 19 [cited 2022 Jan 16]; 337 (7662): 170–173. Reference Source 12. Østensen M, Förger F: Management of RA medications in pregnant patients. Nat. Rev. Rheumatol. 2009 [cited 2022 Jan 16]; 5 (7): 382–390. PubMed Abstract | Publisher Full Text 13. Palmsten K, Bandoli G, Watkins J, et al. : Oral Corticosteroids and Risk of Preterm Birth in the California Medicaid Program. J Allergy Clin Immunol Pract. 2020 Aug 11 [cited 2022 Jan 16]; 9 (1): 375–384.e5. PubMed Abstract | Publisher Full Text Reference Source 14. Wieczorek A, Perani C v, Nixon M, et al. : Sex-specific regulation of stress-induced fetal glucocorticoid surge by the mouse placenta. Am. J. Physiol. Endocrinol. Metab. 2019 Jul 1; 317 (1): E109–E120. PubMed Abstract | Publisher Full Text 15. Hutter S, Hepp P, Hofmann S, et al. : Glucocorticoid receptors α and β are modulated sex specifically in human placentas of intrauterine growth restriction (IUGR). Arch. Gynecol. Obstet. 2019 Aug 14; 300 (2): 323–335. PubMed Abstract | Publisher Full Text 16. Østensen M, Khamashta M, Lockshin M, et al. : Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 2006; 8 (3): 209. PubMed Abstract | Publisher Full Text 17. Lateef A, Petri M: Managing lupus patients during pregnancy. Best Pract. Res. Clin. Rheumatol. 2013 Jun; 27 (3): 435–447. PubMed Abstract | Publisher Full Text 18. Page MJ, McKenzie JE, Bossuyt PM, et al. : The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29 [cited 2022 Jan 16]; 372. Reference Source 19. Brown MA, Magee LA, Kenny LC, et al. : Hypertensive Disorders of Pregnancy. Hypertension. 2018 Jul; 72 (1): 24–43. Publisher Full Text 20. ACOG Practice Bulletin No. 202 Summary: Gestational Hypertension and Preeclampsia. Obstet. Gynecol. 2019 Jan 1 [cited 2022 Jan 16]; 133 (1): 211–214. Reference Source 21. ACOG Practice Bulletin No. 188: Prelabor Rupture of Membranes. Obstet. Gynecol. 2018 Jan 1 [cited 2022 Jan 16]; 131 (1): e1–14. PubMed Abstract | Publisher Full Text 22. ACOG committee opinion no. 560: Medically indicated late-preterm and early-term deliveries. Obstet. Gynecol. 2013 [cited 2022 Jan 16]; 121 (4): 908–910. PubMed Abstract 23. Metz TD, Berry RS, Fretts RC, et al. : Management of Stillbirth. The American College of Obstetricians and Gynecologists. 2009 [cited 2022 Jan 16]. Reference Source 24. Bombardier C, Gladman DD, Urowitz MB, et al. : Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 [cited 2022 Jan 16]; 35 (6): 630–640. PubMed Abstract | Publisher Full Text 25. Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. : Assessing disease activity in SLE patients during pregnancy. Lupus. 1999 [cited 2022 Jan 16]; 8 (8): 677–684. PubMed Abstract | Publisher Full Text 26. Harrington JT: The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthritis in rheumatology practice. J. Rheumatol. 2009 May [cited 2022 Jan 16]; 36 (5): 925–929. PubMed Abstract | Publisher Full Text 27. Gladman DD, Ibañez D, Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002 [cited 2022 Jan 16]; 29 (2). PubMed Abstract Reference Source 28. ICD-10: international statistical classification of diseases and related health problems: tenth revision.[cited 2022 Jan 16]. Reference Source 29. Simhan HN: Practice Bulletin No. 159: Management of Preterm Labor. Obstet. Gynecol. 2016 [cited 2022 Jan 16]; 127 (1): e29–e38. Reference Source 30. ACOG Practice Bulletin No. 204: Fetal Growth Restriction. Obstet. Gynecol. 2019 Feb 1 [cited 2022 Jan 16]; 133 (2): e97–e109. Publisher Full Text Reference Source 31. Sammaritano LR, Bermas BL, Chakravarty EE, et al. : 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 Apr 1 [cited 2022 Jan 16]; 72 (4): 529–56. PubMed Abstract | Publisher Full Text 32. Clark CA, Spitzer KA, Nadler JN, et al. : Preterm deliveries in women with systemic lupus erythematosus. J. Rheumatol. 2003 Oct; 30 (10): 2127–2132. PubMed Abstract 33. Dey ID, Coleman J, Kwarko H, et al. : Outcome of pregnancy in patients with systemic lupus erythematosis at Korle-bu Teaching Hospital. Ghana Med. J. 2016 Jun 1; 50 (2): 72–77. PubMed Abstract | Publisher Full Text | Free Full Text 34. Doria A, Cutolo M, Ghirardello A, et al. : Steroid Hormones and Disease Activity During Pregnancy in Systemic Lupus Erythematosus.2002. 35. Englert HJ, Derue GM, Loizou S, et al. : Pregnancy and Lupus: Prognostic Indicators and Response to Treatment. Q. J. Med. 1988; 66 . PubMed Abstract Reference Source 36. Foocharoen C, Nanagara R, Salang L, et al. : Pregnancy and Disease Outcome in Patients with Systemic Lupus Erythematosus (SLE): A Study at Srinagarind Hospital. J. Med. Assoc. Thail. 2009; 92 : 167–174. PubMed Abstract Reference Source 37. Kobayashi N, Yamada H, Kishida T, et al. : Hypocomplementemia correlates with intrauterine growth retardation in systemic lupus erythematosus. Am. J. Reprod. Immunol. 1999; 42 (3): 153–159. PubMed Abstract | Publisher Full Text 38. Louthrenoo W, Trongkamolthum T, Kasitanon N, et al. : Predicting factors of adverse pregnancy outcomes in Thai patients with systemic lupus erythematosus: A STROBE-compliant study. Medicine. 2021 Feb 5; 100 (5): e24553. PubMed Abstract | Publisher Full Text 39. Murata T, Kyozuka H, Fukuda T, et al. : Maternal disease activity and serological activity as predictors of adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective chart review. Arch. Gynecol. Obstet. 2021. PubMed Abstract | Publisher Full Text 40. Oishi Y, Ikeuchi H, Hamatani H, et al. : Pregnancy outcomes in patients with systemic lupus erythematosus with or without a history of lupus nephritis. Clin. Exp. Nephrol. 2021 Aug 1; 25 (8): 835–843. Publisher Full Text 41. Takahashi K, Mimura K, Kanagawa T, et al. : Disease flare-ups and obstetric outcomes in pregnant women with systemic lupus erythematosus Hypertension Research in Pregnancy. Hypertens. Res. Pregnancy. 2013; 1 : 103–107. Publisher Full Text 42. Ueda A, Chigusa Y, Mogami H, et al. : Predictive factors for flares of established stable systemic lupus erythematosus without anti-phospholipid antibodies during pregnancy. J. Matern. Fetal Neonatal Med. 2020: 1–6. PubMed Abstract | Publisher Full Text 43. Zhang LL, Shu H, Zhang S, et al. : Pregnancy outcomes and risk factors in pregnant women with systemic lupus erythematosus. Clin. Exp. Obstet. Gynecol. 2020 Apr 15; 47 (2): 189–193. Publisher Full Text 44. Bundhun PK, Soogund MZS, Huang F: Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016. J. Autoimmun. 2017 May 1 [cited 2022 Jan 16]; 79 : 17–27. PubMed Abstract | Publisher Full Text 45. Lunghi L, Pavan B, Biondi C, et al. : Use of glucocorticoids in pregnancy. Curr. Pharm. Des. 2010 Dec 19 [cited 2022 Jan 16]; 16 (32): 3616–3637. Publisher Full Text Reference Source 46. Bandoli G, Palmsten K, Forbess Smith CJ, et al. : A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes. Rheum. Dis. Clin. N. Am. 2017 Aug 1 [cited 2022 Jan 16]; 43 (3): 489–502. PubMed Abstract | Publisher Full Text 47. Suryantoro SD: Data of High-dose vs Low-dose Steroid in Pregnancy Patients with Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-analysis. figshare. [Dataset].2022. Publisher Full Text Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 19 May 2022 ADD YOUR COMMENT Comment Author details Author details 1 Department of Internal Medicine, Faculty of Medicine Universitas Airlangga, Surabaya, 60132, Indonesia 2 Universitas Airlangga Hospital, Surabaya, 60115, Indonesia 3 Department of Cardiology and Vascular Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia 4 Department of Pulmonology and Respiratory Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia 5 Universitas Airlangga, Surabaya, 60132, Indonesia 6 Department of Obstetrics and Gynecology, Universitas Airlangga, Surabaya, 60132, Indonesia 7 Department of Nephrology, Jutendo University, Tokyo, 113-8421, Japan Mochammad Thaha Roles: Conceptualization, Data Curation, Project Administration, Supervision Mochamad Yusuf Alsagaff Roles: Investigation, Methodology, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing Satriyo Dwi Suryantoro Roles: Investigation, Project Administration, Supervision Mutiara Rizky Hayati Roles: Investigation, Methodology Hendri Susilo Roles: Investigation, Supervision, Writing – Review & Editing Alfian Nur Rosyid Roles: Investigation, Supervision, Writing – Review & Editing Tri Pudy Asmarawati Roles: Data Curation, Formal Analysis, Investigation, Methodology, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing Emil Prabowo Roles: Investigation, Software, Visualization, Writing – Original Draft Preparation Ibrahim Syamsuri Roles: Investigation, Software, Visualization, Writing – Original Draft Preparation Rais Hakim Roles: Investigation, Writing – Original Draft Preparation Muhammad Ilham Aldika Akbar Roles: Validation, Writing – Review & Editing Cahyo Wibisono Nugroho Roles: Supervision, Validation, Writing – Review & Editing Yusuke Suzuki Roles: Validation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (1) version 1 Published: 19 May 2022, 11:543 https://doi.org/10.12688/f1000research.109908.1 Copyright © 2022 Thaha M et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Thaha M, Alsagaff MY, Dwi Suryantoro S et al. High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis [version 1; peer review: 1 approved] . F1000Research 2022, 11 :543 ( https://doi.org/10.12688/f1000research.109908.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 19 May 2022 Views 0 Cite How to cite this report: Borba EF. Reviewer Report For: High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis [version 1; peer review: 1 approved] . F1000Research 2022, 11 :543 ( https://doi.org/10.5256/f1000research.121463.r148772 ) The direct URL for this report is: https://f1000research.com/articles/11-543/v1#referee-response-148772 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 30 Aug 2022 Eduardo F. Borba , Rheumatology Division, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil Approved VIEWS 0 https://doi.org/10.5256/f1000research.121463.r148772 The objective of this paper is to perform a systematic review and meta-analysis in order to evaluate the effect on high-dose vs low dose of steroid in maternal and fetal outcomes in patients with systemic lupus erythematosus (SLE) and lupus ... Continue reading READ ALL The objective of this paper is to perform a systematic review and meta-analysis in order to evaluate the effect on high-dose vs low dose of steroid in maternal and fetal outcomes in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN). This is a very important issue in this disease. Some minor questions arise: Authors should revise all the text for grammatical errors. Title: OK. Abstract: OK. Keywords: Please use “therapy” instead of “health”. Introduction: Please insert some comments about a recent review that provide recommendations for therapy during pregnancy in SLE (reference #31) and provide a short description of it in order to describe the main suggestions of this paper. In fact, authors used these recommendations for defining high and low steroid dose (Methods section). Patients and methods: Interesting design and selection. Outcomes were well-defined. Methods were appropriate for analysis. Results: No further comments. Discussion: In the same way, authors should include comments in this section about the review that provides recommendations for therapy during pregnancy in SLE (reference #31). Authors should describe these recommendations and compare to those identified in their study. This suggestion will highlight their findings and make clear their conclusions. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Yes Are the conclusions drawn adequately supported by the results presented in the review? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Clinical Reserch in Rhematology - Associate Professor in my Institution - University of Sao Paulo - Brazil I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Borba EF. Reviewer Report For: High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis [version 1; peer review: 1 approved] . F1000Research 2022, 11 :543 ( https://doi.org/10.5256/f1000research.121463.r148772 ) The direct URL for this report is: https://f1000research.com/articles/11-543/v1#referee-response-148772 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 19 May 2022 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 Version 1 19 May 22 read Eduardo F. Borba , University of São Paulo, São Paulo, Brazil Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Borba E. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 30 Aug 2022 | for Version 1 Eduardo F. Borba , Rheumatology Division, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil 0 Views copyright © 2022 Borba E. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The objective of this paper is to perform a systematic review and meta-analysis in order to evaluate the effect on high-dose vs low dose of steroid in maternal and fetal outcomes in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN). This is a very important issue in this disease. Some minor questions arise: Authors should revise all the text for grammatical errors. Title: OK. Abstract: OK. Keywords: Please use “therapy” instead of “health”. Introduction: Please insert some comments about a recent review that provide recommendations for therapy during pregnancy in SLE (reference #31) and provide a short description of it in order to describe the main suggestions of this paper. In fact, authors used these recommendations for defining high and low steroid dose (Methods section). Patients and methods: Interesting design and selection. Outcomes were well-defined. Methods were appropriate for analysis. Results: No further comments. Discussion: In the same way, authors should include comments in this section about the review that provides recommendations for therapy during pregnancy in SLE (reference #31). Authors should describe these recommendations and compare to those identified in their study. This suggestion will highlight their findings and make clear their conclusions. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Yes Are the conclusions drawn adequately supported by the results presented in the review? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Clinical Reserch in Rhematology - Associate Professor in my Institution - University of Sao Paulo - Brazil I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Borba EF. Peer Review Report For: High-dose vs low-dose steroid in pregnancy patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis [version 1; peer review: 1 approved] . F1000Research 2022, 11 :543 ( https://doi.org/10.5256/f1000research.121463.r148772) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-543/v1#referee-response-148772 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "High-dose vs low-dose steroid in pregnancy...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/11-543/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/11-543/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/11-543/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Thaha M et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/11-543/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/11-543", templates : { twitter : "High-dose vs low-dose steroid in pregnancy patients with systemic.... Thaha M et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/11-543/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/109908/121463") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "121463"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "216065": 0, "216071": 0, "216068": 0, "216074": 0, "229640": 0, "216077": 0, "144146": 0, "216083": 0, "144147": 0, "216080": 0, "229648": 0, "144150": 0, "229655": 0, "216086": 0, "144148": 0, "144149": 0, "216090": 0, "211098": 0, "216089": 0, "211103": 0, "139804": 0, "139805": 0, "229660": 0, "148771": 0, "229665": 0, "148774": 0, "148775": 0, "148772": 14, "148773": 0, "211108": 0, "148776": 0, "211113": 0, "148777": 0, "211118": 0, "233395": 0, "233394": 0, "211121": 0, "233399": 0, "211126": 0, "233398": 0, "233397": 0, "233396": 0, "233403": 0, "211130": 0, "233401": 0, "138430": 0, "233407": 0, "138431": 0, "211134": 0, "233405": 0, "138434": 0, "211139": 0, "270276": 0, "270277": 0, "138432": 0, "270278": 0, "138433": 0, "229696": 0, "270279": 0, "270272": 0, "270273": 0, "270274": 0, "270275": 0, "225098": 0, "270280": 0, "225100": 0, "225111": 0, "284496": 0, "284497": 0, "225115": 0, "225114": 0, "225113": 0, "225112": 0, "229720": 0, "225118": 0, "225117": 0, "225116": 0, "229735": 0, "307681": 0, "307682": 0, "145394": 0, "229746": 0, "229631": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "f5dc5f9a-1734-48dd-8cf6-16099e3315ab"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });